Skip to main content
. 2019 Jan 9;8:557. doi: 10.3389/fonc.2018.00557

Figure 2.

Figure 2

Forest plot of meta-analysis of the progression-free survival (PFS) showing comparison of ALK inhibitors to chemotherapy in ALK positive NSCLC.